OCTP Aktienübersicht Oxford Cannabinoid Technologies Holdings Plc, ein pharmazeutisches Unternehmen, beschäftigt sich mit der Forschung, Entwicklung und Vermarktung von verschreibungspflichtigen Medikamenten auf Cannabinoidbasis. Mehr Details
Risikoanalyse + 1 mehr Risiko
Alle Risikoprüfungen anzeigen Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
Oxford Cannabinoid Technologies Holdings Plc Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Oxford Cannabinoid Technologies Holdings Historische Aktienkurse Aktueller Aktienkurs UK£0.0011 52-Wochen-Hoch UK£0.014 52-Wochen-Tief UK£0.00075 Beta 0.82 1 Monat Veränderung -67.14% 3 Monate Veränderung -73.26% 1 Jahr Veränderung -89.78% 3 Jahre Veränderung -97.39% 5 Jahre Veränderung n/a Veränderung seit IPO -97.70%
Aktuelle Nachrichten und Updates Oxford Cannabinoid Technologies Intends Cancellation of Listing of its Ordinary Shares on the Standard Segment of the FCA's Official List May 09
New minor risk - Shareholder dilution Mar 04 Oxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024 Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million. Feb 15
New major risk - Share price stability Jan 31
Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024 Jan 23 Weitere Updates anzeigen Oxford Cannabinoid Technologies Intends Cancellation of Listing of its Ordinary Shares on the Standard Segment of the FCA's Official List May 09
New minor risk - Shareholder dilution Mar 04 Oxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024 Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million. Feb 15
New major risk - Share price stability Jan 31
Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024 Jan 23
New minor risk - Financial data availability Jan 15
Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2 Jan 10
Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive Director Nov 15
Oxford Cannabinoid Technologies Holdings plc Announces Phase I Clinical Trial Results for Lead Drug Candidate OCT461201 Oct 10
New major risk - Share price stability Oct 08
Oxford Cannabinoid Technologies Holdings plc Announces Final Dose Administered in Phase I Clinical Trial Sep 25
Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023 Aug 31
Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023 Aug 22
New major risk - Financial data availability Jul 26
Oxford Cannabinoid Technologies Holdings plc Announces Expansion into Oncology Potential New Cannabinoid-Based Treatment of Cancer Malignancies Jul 18
Oxford Cannabinoid Technologies Holdings plc Announces Appointment of Tim Corn as Chief Medical Officer Jun 09
Oxford Cannabinoid Technologies Holdings plc Announces Mhra and Rec 2 Approval of Phase I Clinical Trial Application May 19
Oxford Cannabinoid Technologies Holdings plc Announces Appointment of General Counsel and Company Secretary Jan 16
Oxford Cannabinoid Technologies Holdings plc Submits Combined Clinical Trials Application for Its Lead Programme, OCT461201 Jan 06
Oxford Cannabinoid Technologies Holdings plc Announces Executive Changes Dec 05
Less than half of directors are independent Nov 16
Oxford Cannabinoid Technologies Holdings plc Announces Management Changes Oct 17
Karen Lowe to Step Down as Group Finance Director of Oxford Cannabinoid Technologies Holdings plc Aug 26
Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2022 Jul 25
Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2022 Results on Jul 25, 2022 Jul 20
Less than half of directors are independent Apr 27
Oxford Cannabinoid Technologies Holdings Plc Announces Formation of Scientific Advisory Board Apr 26
Oxford Cannabinoid Technologies Holdings plc Announces Updates on Lead Programme 1 and Programme 2 Apr 01 Oxford Cannabinoid Technologies Holdings plc Announces Data from Pre-Clinical Study of OCT461201 Shows Positive Results Mar 10
Oxford Cannabinoid Receives a Letter from GHS Capital Limited Feb 19
Oxford Cannabinoid Technologies Holdings plc Announces Board Changes Feb 01
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 29
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 29
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 29
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 29
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 28
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 27
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 26
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25
Non-Executive Director & Co-Founder Gavin Sathianathan has left the company Nov 25 Aktionärsrenditen OCTP GB Pharmaceuticals GB Markt 7D -32.4% -2.0% -2.2% 1Y -89.8% -3.5% 2.4%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: OCTP unter dem Niveau der Branche UK Pharmaceuticals , die im vergangenen Jahr eine Rendite von -3.5% erzielte.
Rendite vs. Markt: OCTP hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 2.4 erzielte.
Preisvolatilität Is OCTP's price volatile compared to industry and market? OCTP volatility OCTP Average Weekly Movement 21.4% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stabiler Aktienkurs: OCTPDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.
Volatilität im Zeitverlauf: OCTPDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 14% auf 21% gestiegen.
Über das Unternehmen Oxford Cannabinoid Technologies Holdings Plc, ein pharmazeutisches Unternehmen, beschäftigt sich mit der Forschung, Entwicklung und Vermarktung von verschreibungspflichtigen Medikamenten auf Cannabinoidbasis. Der führende Medikamentenkandidat OCT461201, ein CB2-Rezeptor, befindet sich in der klinischen Phase I zur Behandlung von chemotherapiebedingter peripherer Neuropathie und Reizdarmsyndrom sowie von neuropathischen und viszeralen Schmerzzuständen. Das Unternehmen entwickelt außerdem OCT130401, das sich in der präklinischen Entwicklung für die Behandlung der Trigeminusneuralgie befindet.
Mehr anzeigen Oxford Cannabinoid Technologies Holdings Plc's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Oxford Cannabinoid Technologies Holdings im Vergleich zum Marktanteil des Unternehmens? OCTP grundlegende Statistiken Marktanteil UK£1.25m Gewinn(TTM ) -UK£4.24m Umsatz(TTM ) n/a
0.0x Kurs-Umsatz-Verhältnis
-0.3x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) OCTP Gewinn- und Verlustrechnung (TTM ) Einnahmen UK£0 Kosten der Einnahmen UK£2.33m Bruttogewinn -UK£2.33m Sonstige Ausgaben UK£1.91m Umsatz -UK£4.24m
Zuletzt gemeldete Gewinne
Oct 31, 2023
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) -0.0039 Bruttomarge 0.00% Nettogewinnspanne 0.00% Schulden/Eigenkapital-Verhältnis 0%
Wie hat sich OCTP auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2024/06/06 23:31 Aktienkurs zum Tagesende 2024/06/06 00:00 Gewinne 2023/10/31 Jährliche Einnahmen 2023/04/30
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .
Analysten-Quellen Oxford Cannabinoid Technologies Holdings Plc wird von 1 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Soo Romanoff Edison Investment Research
0 weitere Analysten anzeigen 
